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Abstract
Background: Since the start of the 2009 influenza A pandemic (H1N1pdm), the World Health Organization and its member
states have gathered information to characterize the clinical severity of H1N1pdm infection and to assist policy makers to
determine risk groups for targeted control measures.
Methods and Findings: Data were collected on approximately 70,000 laboratory-confirmed hospitalized H1N1pdm
patients, 9,700 patients admitted to intensive care units (ICUs), and 2,500 deaths reported between 1 April 2009 and 1
January 2010 from 19 countries or administrative regions—Argentina, Australia, Canada, Chile, China, France, Germany,
Hong Kong SAR, Japan, Madagascar, Mexico, the Netherlands, New Zealand, Singapore, South Africa, Spain, Thailand, the
United States, and the United Kingdom—to characterize and compare the distribution of risk factors among H1N1pdm
patients at three levels of severity: hospitalizations, ICU admissions, and deaths. The median age of patients increased with
severity of disease. The highest per capita risk of hospitalization was among patients,5 y and 5–14 y (relative risk [RR] = 3.3
and 3.2, respectively, compared to the general population), whereas the highest risk of death per capita was in the age
groups 50–64 y and $65 y (RR = 1.5 and 1.6, respectively, compared to the general population). Similarly, the ratio of
H1N1pdm deaths to hospitalizations increased with age and was the highest in the $65-y-old age group, indicating that
while infection rates have been observed to be very low in the oldest age group, risk of death in those over the age of 64 y
who became infected was higher than in younger groups. The proportion of H1N1pdm patients with one or more reported
chronic conditions increased with severity (median = 31.1%, 52.3%, and 61.8% of hospitalized, ICU-admitted, and fatal
H1N1pdm cases, respectively). With the exception of the risk factors asthma, pregnancy, and obesity, the proportion of
patients with each risk factor increased with severity level. For all levels of severity, pregnant women in their third trimester
consistently accounted for the majority of the total of pregnant women. Our findings suggest that morbid obesity might be
a risk factor for ICU admission and fatal outcome (RR = 36.3).
Conclusions: Our results demonstrate that risk factors for severe H1N1pdm infection are similar to those for seasonal
influenza, with some notable differences, such as younger age groups and obesity, and reinforce the need to identify and
protect groups at highest risk of severe outcomes.
Please see later in the article for the Editors’ Summary.
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Introduction
In late April 2009, a novel strain of influenza A H1N1 was
identified in Mexico and the United States. This virus quickly
spread globally, and on June 11, 2009, the World Health
Organization (WHO) declared a pandemic alert phase 6,
indicating that the first influenza pandemic of the 21st century
had begun [1–3]. Many Northern hemisphere temperate countries
experienced their first wave of infection during the spring and
summer months of 2009, followed by an early 2009 fall influenza
season. Southern hemisphere temperate countries experienced the
first wave of infection during their winter of 2009, and at the time
of writing are finishing their winter 2010 season. By the end of
2009, the peak of the local influenza epidemic had passed in most
countries around the world [4].
Since the start of the pandemic, WHO and member states have
been gathering information to characterize the clinical picture and
patterns of risk associated with the 2009 pandemic influenza A
H1N1 (H1N1pdm) virus infection to assist public health policy
makers in targeting of vaccination strategies, antiviral use, and
other control measures. Risk factors for severe disease following
seasonal influenza infection have been well documented in many
countries, and include chronic medical conditions such as
pulmonary, cardiovascular, renal, hepatic, neuromuscular, hema-
tologic, and metabolic disorders, some cognitive conditions, and
immunodeficiency [5–7]. The risk associated with seasonal
influenza during pregnancy is less well documented but in
previous pandemics, pregnant women were identified as being at
increased risk of adverse outcomes, and many countries include
healthy pregnant women among the seasonal influenza high risk
groups as well [8–11]. However, early in the 2009 H1N1
pandemic, risk factors for severe disease following infection were
largely unknown. Following a series of teleconferences organized
by WHO with clinicians treating H1N1pdm patients around the
world, it appeared that the most common risk factors for severe
H1N1pdm disease were similar to those for seasonal influenza
infection; however, several new factors (e.g., obesity and
tuberculosis [TB]) were also observed with high frequency in
some countries. It was also noted that members of indigenous/
aboriginal communities in some countries appeared to be
overrepresented among severe cases [12].
While many countries have recently reported data on the
association between severe H1N1pdm influenza and the presence
of a variety of underlying risk factors (e.g., [13–26]), these data are
presented in different formats, making direct comparisons across
countries difficult, and no clear consensus has emerged for some
conditions. This paper presents data from approximately 70,000
lab-confirmed hospitalized and 2,500 fatal cases of H1N1pdm
infection in 19 countries or administrative regions—Argentina,
Australia, Canada, Chile, China, France, Germany, Hong Kong
SAR, Japan, Madagascar, Mexico, the Netherlands, New
Zealand, Singapore, South Africa, Spain, Thailand, the United
States, and the United Kingdom—in order to characterize and
compare the distribution of underlying risk factors among
H1N1pdm confirmed patients who were hospitalized, admitted
to an intensive care unit (ICU), or died, and to assess the frequency
and distribution of known and new potential risk factors for severe
H1N1pdm infection.
Methods
This study compares data primarily obtained from surveillance
programs of the Ministries of Health or National Public Health
Institutes of 19 countries or administrative regions covering the
period 1 April 2009 to 1 January 2010. Countries were asked to
provide risk factor data on laboratory-confirmed cases using a
standardized format for this analysis. The data were collected in
the course of routine surveillance, methods of which varied from
country to country [27–49], and were reported anonymously and
as aggregate data; hence, no ethics approval was required. It
should be noted that considerable effort was put into negotiating
permission for these data to be presented in these formats. As
many countries would not be willing to have their country-specific
data published in direct comparisons with others, we are taking the
approach of publishing data from a wide range of countries and
showing the variability observed, so that results from specific
studies can be compared with the international results reported
here.
Potential risk factors were grouped into four categories: age,
chronic medical illnesses, pregnancy (by trimester), and ‘‘other,’’
which included conditions that were not previously considered as
risk factors for severe influenza outcomes, such as obesity,
membership in a vulnerable social or ethnic group, and TB.
Details of the standardized format and definitions of each of the
conditions are provided in Text S1.
Risk factor information was collected separately for three levels
of severity of illness in laboratory-confirmed patients: hospitaliza-
tions, admissions to ICU, and fatalities by country. Details of the
available data from countries by risk factor and severity level are
provided in Text S1. For each risk factor, except for pregnancy,
the percentage of patients who were hospitalized, were admitted to
ICU, and died was calculated using the total number of cases
reported in each severity category. To evaluate the risk associated
with pregnancy, the ratio of pregnant women to all women of
childbearing age (age 15–49 y) in each level of severity was used to
describe the differences between levels. The overall median and
interquartile ranges (IQRs) were calculated for each risk factor
using all available data. In addition, where available, countries
provided baseline comparison data for prevalence of the risk factor
in the general population (details and sources provided in Text
S1). Data on age were provided by age groups (,5, 5–14, 15–24,
25–49, 50–64, and $65 y).
Risk of Severe Disease
Where data were available, we calculated the risk for severe
H1N1pdm outcomes (hospitalization, admission to ICU, and
death) compared to the prevalence of risk factors in the general
population (relative risk [RR] of hospitalization [RRhosp], RR of
ICU admission [RRICU], and RR of death [RRdeath]) by country.
See Text S1 for more information and formulae.
For pregnancy, we first calculated the proportion of women of
childbearing age who were pregnant in each severity category by
dividing the number of pregnant women in that category by the
number of women of childbearing age in that category. As
individual case data were not available, we calculated the number
of fertile women in each level of severity using the numbers of
patients in each level of severity in the age range between 15 and
49 y multiplied by the percentage for that severity level that was
female. Unless provided by the country, the point prevalence of
pregnant women in the general population (the denominator of
the RR calculation) was calculated using crude birth rate and 2010
United Nations population estimates [50] to derive the annual
number of pregnancies, multiplied by 40/52 and without adjusting
for seasonality of pregnancies, abortions, miscarriages, early
deliveries, or multiple births. We also calculated the country-
specific odds ratios (ORs) and 95% confidence intervals (CIs) for
death given hospitalization separately for each risk factor (i.e., the
odds of death given hospitalization and a specific risk factor),
thereby comparing the odds of death in one group (e.g., among
Risk Factors for H1N1pdm Severity
PLoS Medicine | www.plosmedicine.org 3 July 2011 | Volume 8 | Issue 7 | e1001053
hospitalized patients with asthma) with the odds of death in all
other hospitalized patients combined (e.g., among hospitalized
patients without asthma) (individual country ORs not shown). We
then used the I2 statistic to quantify the percentage of variation
across countries that is due to true underlying heterogeneity in the
ORs rather than chance variability [51]. The I2 statistics for all
examined risk factors indicated that there was substantial true
underlying variation between ORs from different countries. We
undertook meta-analyses with and without random effects in
parallel to describe the distribution of the OR estimates across the
countries for which data were available for analysis. As expected,
given the heterogeneity observed between countries, the random
effects meta-analysis yielded wider CIs. We conservatively report
the pooled estimates from the random effects meta-analysis to
describe the distribution of the OR estimates across the countries
for which data were available for analysis. Underlying the random
effects approach is the assumption that, although the individual
countries give rise to different OR estimates, these estimates arise
from a distribution with a central value, the estimate of which is
referred to as the ‘‘pooled OR,’’ and normally distributed
variability around this value. However, because of the limited
number of countries in each analysis, the number of random
effects is too small for diagnostics such as quantile–quantile plots to
demonstrate whether the assumption of a normal distribution is
valid.
Finally, with a meta-analysis of data from such diverse countries
as those included in this study, reasons for heterogeneity were
sought through exploratory meta-regression analyses. However,
because of the limited number of countries included in the meta-
regression models, and with country being the unit of analysis, the
meta-regression results were not considered to be robust and so are
not presented or discussed further [52].
All meta-analyses and meta-regression techniques were per-
formed using Stata version 10 (StataCorp).
Results
Data were collected on approximately 70,000 patients requiring
hospitalization, 9,700 patients admitted to ICU, and 2,500
fatalities from 19 countries and administrative regions across the
Americas, Asia, Europe, and Africa.
Age and Gender
Approximately half of all patients included in this analysis in
each level of severity were female (49.8%, 47.0%, and 44.7% of all
hospitalized, ICU-admitted, and fatal H1N1pdm cases, respec-
tively). This proportion did not vary significantly by country
(Table 1). Age was associated with increased risk of poor outcome,
as indicated by several different parameters. The median age of
patients increased with increasing levels of severity (Table 1).
Among hospitalized patients, the median age within each country
ranged from 7 y in Japan to 38 y in Spain, with a median reported
value among all countries that provided data (n = 14) of 19 y (IQR
14.8–27.5); among patients admitted to ICU, the median age
within each country ranged from 28 y in China to 49.5 y in Hong
Kong SAR, with a median value among all countries that
provided data (n = 9) of 42 y (IQR 35.0–45.0); and among fatal
cases, median age within each country ranged from 30 y in China
to 56 y in Hong Kong SAR, with a median value among all
countries that provided data (n = 13) of 46 y (IQR 37.0–42.0).
When the age distribution of the proportion of patients in each
level of severity was compared to the distribution in the general
population, the RR was highest in the age groups ,5 y and
5–14 y (RRhosp = 3.3 and 3.2, respectively) but the RR of death
was highest in the age groups 50–64 y and $65 y (RRdeath = 1.6
and 1.7, respectively) (Figure 1). The ratio of H1N1pdm deaths to
hospitalizations increased with age and was the highest in the
$65-y-old age group in all countries for which data were available
(Figure 2).
Chronic Illness
The proportion of H1N1pdm patients with at least one chronic
medical condition generally increased with severity (median
among all countries that provided data was 31.1% [n = 14],
52.3% [n = 10], and 61.8% [n = 16] of hospitalized, ICU-admitted,
and fatal H1N1pdm cases, respectively (Table 1). This pattern was
observed for most countries (individual country data not shown).
For nearly every individual risk factor under study, the prevalence
increased significantly with severity level. Chronic respiratory
conditions excluding asthma (median = 10.3%, 17.2%, and
20.4%, respectively) and asthma (median = 17.6%, 9.8%, and
5.3%, respectively) were the risk factors most often reported
among severe cases, followed closely by diabetes (median = 9.0%,
13.6%, and 14.4%, respectively) and chronic cardiac conditions
(median = 7.1%, 10.9%, and 12.1%, respectively). The pooled OR
for death given hospitalization was significantly above one for each
risk factor listed, with the exception of asthma, and was highest for
chronic liver disease and immunocompromised patients (Figure 3).
The risk of severe disease due to H1N1 infection, including
hospitalization and death, was elevated for every chronic condition
for which data were available (Table 1). Notably, the RR for fatal
disease due to H1N1pdm infection was elevated for asthma
(median RRdeath = 1.7 [IQR 1.5–2.1]) and not markedly different
from the RR associated with hospitalizations (median RRhosp = 1.8
[IQR 1.2–2.6]). Data on chronic illness rates in the general
population were not available from enough countries to permit an
assessment of the relative magnitude of risk associated with various
conditions with certainty.
Pregnancy
The proportions of women of childbearing age who were
hospitalized with H1N1 and were pregnant as part of all
hospitalizations (median of all country data = 17.4% [IQR 13.5–
30.2]), who were admitted to ICU (median of all country
data = 15.0% [IQR 9.4–24.2]), and who died (median of all
country data = 6.9% [0.0–9.1]) varied within each country.
Pregnant women in their third trimester consistently accounted
for more than half of all pregnant women among hospitalized,
ICU-admitted, and fatal cases. However, with the exception of
China, Thailand, and the US, the proportion of pregnant women
decreased with increasing level of severity, and the pooled OR for
death given hospitalization during pregnancy was below 1 (pooled
OR = 0.6, 95% CI 0.2–2.5).
Pregnant women with H1N1pdm infection were at higher risk
of hospitalization than women of childbearing age in the general
population without H1N1pdm infection, with an unadjusted RR
of hospitalization ranging from 3.5 in Germany to 25.3 in France
(median RRhosp = 6.8, n = 10 countries). The unadjusted RR of
death, while elevated compared to non-pregnant women in more
than half of countries, was generally lower than that for
hospitalization, with a median RRdeath of 1.9 (n = 11 countries).
Four areas (Japan, the Netherlands, Hong Kong SAR, and
Singapore) had a RRdeath of zero.
Other Risk Factors
The proportion of patients with obesity (body mass index [BMI]
$30 or clinically judged as obese) increased with increasing
disease severity and represented a median of 6%, 11.3%, and
Risk Factors for H1N1pdm Severity
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12.0% of all hospitalized, ICU-admitted, and fatal H1N1pdm
cases, respectively, and this pattern was also observed for morbid
obesity (BMI .40), with 3.0%, 5.0%, and 15.2%, respectively
(Table 1). However, this pattern was not consistently reported in
each country. For example, France, Thailand, and China
observed similar proportions of obese patients among ICU-
admitted and fatal cases, while Hong Kong SAR reported a lower
prevalence of obesity among fatal cases than among ICU
admissions. Using data from all countries, the pooled OR for
death given hospitalization for obesity (BMI $30 or clinically
judged as obese) was 2.9 (95% CI 1.3–6.6; Figure 3). Compared to
the general population in the two countries for which data were
available, the risk of death associated with morbid obesity was
increased (mean RRdeath = 36.3 [IQR 22.4–50.1], n = 2).
Canada, Australia, and New Zealand reported significant
disparities in the burden of severe H1N1pdm disease across
different ethnic groups. In these three countries, indigenous
population groups were overrepresented among severe H1N1pdm
cases requiring hospitalization and among fatal cases. In contrast,
in Thailand and Mexico, minority groups were underrepresented
among severe H1N1pdm cases. Taken together, the unadjusted
median RR of hospitalization for H1N1pdm patients among
minority groups was 1.0 (IQR 0.2–3.7) and the median RR of
death was 2.4 (IQR 1.2–3.8). TB data were reported from three
countries, and the incidence increased slightly with level of
severity. The disease was reported in a median of 1.7%, 1.3%, and
2.6% of hospitalized, ICU-admitted, and fatal H1N1pdm cases,
respectively. We were not specifically able to evaluate HIV
Table 1. Risk factors by severity level for select countries and risk of severe disease.
Risk Factora Severity Level
b RR of Severe Disease (IQR)c
nd
Hospitalized
Cases nd
ICU-Admitted
Cases nd Fatal Cases nd RRhosp n
d RRdeath
Age 14 19.0 (14.8–27.5) 9 42.0 (35.0–45.0) 13 46.0 (37.0–52.0) —e —e
Gender (percent female) 12 49.8 (46.2–51.5) 11 47.0 (41.9–50.5) 14 44.7 (41.5–48.7) 12 1.0 (0.8–1.1) 14 0.8 (0.7–1.0)
Chronic medical illness
Respiratory disease 12 10.3 (5.0–21.7) 11 17.2 (10.5–29.9) 16 20.4 (9.3–29.5) 5 3.3 (2.0–5.8) 8 7.8 (4.9–26.6)
Asthma 11 17.6 (10.0–20.4) 9 9.8 (5.6–14.3) 15 5.3 (4.0–10.6) 3 1.8 (1.2–2.6) 6 1.7 (1.5–2.1)
Diabetes 14 9.0 (3.5–12.6) 12 13.6 (9.3–17.3) 17 14.4 (13.0–18.0) 7 0.9 (0.5–1.7) 10 4.0 (3.1–6.9)
Cardiac disease 12 7.1 (3.7–10.9) 11 10.9 (8.8–15.0) 15 12.1 (10.0–16.4) 6 2.0 (1.5–2.2) 8 9.2 (5.4–10.7)
Renal disease 13 4.0 (2.0–5.1) 11 6.3 (3.5–8.4) 16 7.1 (5.0–8.1) 2 4.4 (4.2–4.5) 3 22.7 (21.0–25.4)
Liver disease 9 1.1 (0.3–2.0) 9 2.4 (0.9–5.0) 12 4.9 (2.7–6.0) 3 5.7 (3.2–15.7) 4 17.4 (11.6–28.0)
Neurological disease 11 4.0 (2.5–7.5) 11 7.0 (3.5–9.5) 14 13.9 (5.5–18.4) 2 1.1 (0.9–1.3) 3 13.1 (8.4–32.4)
Immune compromised 13 5.0 (2.0–7.2) 11 6.7 (3.2–18.4) 15 12.5 (7.9–18.4) 2 24.3 (16.1–32.6) 4 27.7 (14.0–66.5)
Cases with $1 chronic
medical illnesses
14 31.1 (19.0–47.1) 10 52.3 (41.1–58.7) 16 61.8 (48.5–67.9) NA NA
Pregnancyf
First trimester 7 2.0 (1.0–3.5) 6 2.0 (1.5–2.5) 5 0.9 (0.0–2.5)
Second trimester 7 7.0 (3.9–9.3) 7 5.0 (1.7–6.2) 5 2.5 (0.0–14.1)
Third trimester 7 9.5 (7.6–21.3) 8 8.0 (4.0–14.6) 6 16.9 (5.1–32.0)
Unknown trimester 8 6.0 (1.9–9.3) 6 2.8 (1.7–3.2) 7 0.0 (0.0–2.1)
Total (any trimester) 10 17.4 (13.5–30.2) 9 15.0 (9.4–24.2) 11 6.9 (0.0–9.1) 10 6.8 (4.5–12.3) 11 1.9 (0.0–2.6)
Obesity
BMI $30 or clinically obese 11 6.0 (1.5–7.5) 8 11.3 (7.9–15.8) 13 12.0 (10.0–21.0) 6 0.6 (0.2–1.8) 7 1.5 (0.9–2.8)
BMI = 30–40 3 7.0 (4.4–16.0) 3 10.0 (6.9–18.5) 4 15.8 (7.7–25.2) NA NA
BMI .40 5 3.0 (1.4–11.5) 5 5.0 (3.4–16.4) 6 15.2 (4.0–30.8) 2 15.0 (9.5–20.4) 2 36.3 (22.4–50.1)
BMI not measured but
judged clinically obese
8 4.3 (1.8–13.3) 4 4.4 (3.4–5.3) 8 7.8 (3.8–17.3) NA NA
Vulnerable social/
ethnic group
4 5.2 (2.3–10.6) 4 5.0 (1.5–10.7) 4 10.1 (5.3–18.5) 4 1.0 (0.2–3.7) 4 2.4 (1.2–3.8)
TB 2 1.7 (0.9–1.8) 2 1.3 (1.0–1.6) 4 2.6 (0.8–5.9) NA NA
aSee Text S1 for definitions of risk factors.
bAll data given as median percent (IQR), except for age, which is median (in years) (IQR).
cRRhosp is the unadjusted RR of hospitalization among H1N1pdm patients with the risk factor compared to the risk of hospitalization among H1N1pdm patients without
the risk factor, and RRdeath is the unadjusted RR of death among H1N1pdm patients with the risk factor compared to the risk of death among H1N1pdm patients
without the risk factor; range of RR provided if $2 countries provided data.
dThe number of countries providing data for cell directly to the right; the full list of countries that provided data for each risk factor is provided in Text S1.
eRRhosp and RRdeath calculated by age group and shown in Figure 1.
fDenominator is women of childbearing age in each level of severity.
NA, not assessed.
doi:10.1371/journal.pmed.1001053.t001
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Figure 1. Relative risk of hospitalization, ICU admission, and death by age group compared to the general population. Countries
included in hospitalization (A) and mortality (C) RRs: Japan, Hong Kong SAR, China, Singapore, Thailand, Chile, Germany, the Netherlands, Spain, New
Zealand, Canada, US, Madagascar (hospitalizations only), and France (deaths only). Countries included in ICU admission RR (B): Japan, Hong Kong SAR,
China, Singapore, Canada, Spain, the Netherlands, US, New Zealand, and South Africa. Dark line represents pooled RR; shaded lines are individual
country RR.
doi:10.1371/journal.pmed.1001053.g001
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incidence because of a paucity of data on HIV in H1N1pdm
patients.
Discussion
Our analysis represents to our knowledge the first comprehen-
sive assessment of the frequency and distribution of risk factors for
severe H1N1pdm infection from a global perspective, with data
from approximately 70,000 patients requiring hospitalization,
9,700 patients admitted to ICU, and 2,500 fatalities from 19
countries and administrative regions around the world. Consistent
with other published data, our results reaffirm that the age
distribution of severe H1N1pdm cases significantly differs from
that of seasonal influenza [53–56]. The highest rates of
hospitalization per capita were in children ,15 y, but the highest
rates of mortality per capita were in persons over 64 y. The low
apparent attack rate in the oldest age group, evidenced by low
rates of hospitalization, and the high odds associated with age in
the fatal group compared to hospitalized cases seems to indicate
that although older adults may have a lower risk of infection, they
have a significantly higher risk of death if they are infected [54,57–
61]. It is likely that increasing prevalence of chronic risk conditions
in the oldest age group contributes to this effect, but our data do
not allow for quantification of this association.
Our results demonstrate that in a significant portion of severe
and fatal cases, patients had preexisting chronic illness, and that
the presence of chronic illness increased the likelihood of death. It
was notable, however, that approximately 2/3 of hospitalized
cases and 40% of fatal cases did not have any identified preexisting
chronic illness. It is unknown how many of these cases had other
risk factors, such as pregnancy, obesity, and substance abuse
(including smoking and alcohol), for which we had insufficient
information in this study. These figures are also dependent on the
completeness of available data for recorded risk factors. As with
seasonal influenza, the most common underlying chronic
conditions among hospitalized patients were respiratory disease,
asthma, cardiac disease, and diabetes. Interestingly, we found that
although asthma was frequently associated with both hospitaliza-
tion and death in most countries, with an increased RR for both,
the OR for death given hospitalization suggested that a higher
proportion of hospitalized cases survived compared to patients
with other conditions. This may represent the occurrence of
manageable influenza-induced exacerbations of asthma prompting
admission that do not progress to viral pneumonia or other fatal
complications, and may also reflect the fact that asthma tends to
occur in younger age groups [62].
Early data suggested that pregnancy might be an important risk
factor for severe disease with H1N1pdm [21,25,63,64]. Our
analysis is consistent with these reports and more recent studies
[47,65], which found an overall trend that pregnant women,
mainly in their third trimester, have a higher incidence of
hospitalization than the general population. Several published
studies have also shown that pregnancy is associated with a higher
risk of ICU admission and fatal outcome [54,58,66,67]. In our
analysis, the risk associated with pregnancy was elevated for both
hospitalization and fatality compared to women of childbearing
age, though the latter association was not consistently observed in
every country. As with asthma, the proportion of pregnant women
Figure 2. Ratio of confirmed H1N1pdm deaths to hospitalizations for selected countries. Countries included in figure: Spain, Singapore,
China, Hong Kong SAR, Canada, the Netherlands, Thailand, Chile, Germany, Japan, US, and New Zealand. Bars represent maximum country ratio.
doi:10.1371/journal.pmed.1001053.g002
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generally decreased with severity level for most of the countries.
Our results suggest that pregnant women with H1N1pdm are
approximately seven times more likely to be hospitalized and two
times more likely to die than non-pregnant women with
H1N1pdm. The greater risk for hospitalization than for death
with H1N1pdm influenza infection during pregnancy may have
resulted from a lower threshold for admitting infected pregnant
women to hospital and/or a more aggressive approach to antiviral
or other treatment for pregnant women. In addition, the
occurrence of non-respiratory complications of pregnancy, such
as hypertension, pre-eclampsia, and premature labor, provoked by
H1N1pdm infection may have increased the risk of hospitalization
while not resulting in death [68]. This would be consistent with
published reports of case series of pregnant patients that list
complications of pregnancy as a common cause of admission
[63,69,70]. The dataset did not allow us to adjust for underlying
conditions in pregnant women, and thus to distinguish between
risks for healthy pregnant women, and pregnant women with
underlying medical conditions; however, we believe that the results
support an approach of early intervention with pregnant women
who develop influenza.
Early in the 2009 pandemic, clinicians from the US reported a
surprisingly high prevalence of morbid obesity, a risk factor not
previously associated with severe outcomes for seasonal influenza
infection, in patients with severe complications of H1N1pdm
infection [71]. Subsequent studies in several countries, including
the US, Mexico, Canada, Spain, Greece, France, Australia, and
New Zealand, reported high proportions of obesity among ICU
admissions and fatal cases [13,20,58,64,72–77]. Our results
provide supportive evidence that obesity may be a risk factor for
severe disease, as seen in the increasing proportion of morbidly
obese patients with severity level and the associated elevated OR.
Our findings also suggest that morbidly obese patients with
H1N1pdm are more likely to die if hospitalized; however, the
results in our analysis were not consistent across all countries. The
association between obesity (or morbid obesity) and severe
outcomes may reflect direct causation (e.g., due to greater
respiratory strain of infection on obese individuals), causation
through other known risk factors (e.g., obesity causes diabetes and
heart disease, which pose an increased risk for severe outcome
[36]), or a noncausal association, if some other factor (e.g., genetic
or dietary) caused both morbid obesity and increased risk of severe
outcome. Unfortunately, our dataset did not allow us to distinguish
among these nonexclusive alternatives.
Indigenous populations and ethnic minorities have been
reported to experience a disproportionately high burden of severe
H1N1pdm infection, particularly in the Americas [14,21,23,36,
64,75,78–80] and the Australasia-Pacific region [43,80–82],
similar to reports during the 1918 influenza pandemic [83–85].
Our analysis of Australian, New Zealand, and Canadian data
concur with these published reports, and while compelling, were
not universal. Neither Thailand nor Mexico observed a signifi-
cantly increased burden of severe H1N1pdm disease among
indigenous or minority populations. Our data are not sufficient to
explain the observed differences in the reported risk of severe
disease among minority groups, but several hypotheses have been
proposed, including a higher prevalence of chronic medical
conditions known to increase risk of severe influenza, delayed or
reduced access to healthcare, cultural differences in healthcare-
seeking behavior and approaches to health, potential differences in
Figure 3. Pooled odds ratio and 95% CIs of risk of death given hospitalization for selected countries. See Text S1 for countries included
in the pooled risk factor ORs.
doi:10.1371/journal.pmed.1001053.g003
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genetic susceptibility, and social inequalities [23,78,80]. More
research is needed to better understand and quantify the increased
risk of severe H1N1pdm disease among these groups. However, an
imperfect understanding of the mechanisms of health disparities
related to severe H1N1pdm disease should not impede the public
health community in undertaking actions to mitigate this risk by
disseminating appropriate public information, targeting outreach
and prevention programs, and involving at-risk population groups
in pandemic planning.
Our analysis has a number of limitations, not least of which is the
wide differences in surveillance systems, case management policies,
and antiviral use in the countries studied. The criteria and
indications for hospital and ICU admission for certain conditions
(e.g., pregnancy and asthma) and by age (e.g., pediatric patients)
varied significantly by country, and may have been somewhat
dependent on capacity for admission, which likely varied over time.
Risk factors are also dependent on the completeness and quality of
data on risk factors reported and classification of death in the
absence of complete testing. These variables could lead to a bias in
the estimate of these conditions among severe cases and could make
direct comparisons across countries difficult. Second, our data do
not consider multiple risk factors for individual H1N1pdm patients.
A lack of individual-level data on underlying medical conditions of
H1N1pdm patients precludes our ability to sufficiently control for
confounding and therefore identify the independent contribution of
individual risk factors for severe disease and death. The differences
observed in risk factors for hospitalization and death among
H1N1pdm patients compared to among seasonal influenza patients,
and the wide range of RR values between countries may be
explained by differences in age structure in the general population.
Several studies have identified important differences in the
proportions of underlying conditions by age among hospitalized
and fatal cases, including, but not limited to, the UK [15,53], the
US [36], Canada [47], and Singapore [39,86].
A third limitation is related to our imperfect calculation of the
point prevalence of pregnancy among women of childbearing age in
the general population. However, we believe that our findings of the
range of RR values for hospitalization and death is valid, but may be
very slightly inflated because of undercounting in the denominator.
The inflationary effect of undercounting is likely greatest for
pregnant women in the first trimester, as we didn’t adjust for
common first trimester events such as miscarriages or abortions, and
in this group there is likely substantial undercounting in the
numerator as well because of women not knowing they are pregnant
in that period. Fourth, the data used in our analysis relied on
hospital records, which were not standardized, and were likely to be
incomplete or vary in quality between hospitals or countries. This
poses a problem in the direct comparativeness between settings.
Despite these limitations, this analysis is the first to our
knowledge to compare risk factors across a variety of countries
using data from a very large number of patients, and we found a
great deal of consistency for much of the data. Clearly, cardiac
disease, chronic respiratory disease, and diabetes are important
risk factors for severe disease that will be especially relevant for
countries with high rates of these illnesses. We provide evidence to
support the concern regarding obesity, particularly morbid
obesity, as a risk factor, though this needs more study. We found
large between-country variations for some important risk factors,
most notably pregnancy, and the reasons for these differences need
more study. There is evidence to suggest that the differences
observed for pregnancy might represent differences in case
management practices, and we believe that the available evidence
supports vaccination and early intervention for pregnant women.
Our study reinforces the need to identify and target high-risk
groups for interventions, such as immunization, information, early
medical advice, and use of antiviral medications. Experience with
the 2009 H1N1 pandemic and the differences observed between
countries have highlighted the need for country-specific surveil-
lance data and global standardization of case definitions and data
collection, and the usefulness of data sharing to aid policy makers
in critical decision making for global influenza epidemics.
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Editors’ Summary
Background. In April 2009, a new strain of influenza A
H1N1 was first identified in Mexico and the United States and
subsequently spread around the world. In June 2009, the
World Health Organization (WHO) declared a pandemic alert
phase 6, which continued until August 2010. Throughout the
pandemic, WHO and member states gathered information to
characterize the patterns of risk associated with the new
influenza A H1N1 virus infection and to assess the clinical
picture. Although risk factors for severe disease following
seasonal influenza infection have been well documented in
many countries (for example, pregnancy; chronic medical
conditions such as pulmonary, cardiovascular, renal, hepatic,
neuromuscular, hematologic, and metabolic disorders; some
cognitive conditions; and immunodeficiency), risk factors for
severe disease following infection early in the 2009 H1N1
pandemic were largely unknown.
Why Was This Study Done? Many countries have recently
reported data on the association between severe H1N1
influenza and a variety of underlying risk factors, but because
these data are presented in different formats, making direct
comparisons across countries is difficult, with no clear
consensus for some conditions. Therefore, to assess the
frequency and distribution of known and new potential risk
factors for severe H1N1 infection, this study was conducted
to collect data (from 1 April 2009 to 1 January 2010) from
surveillance programs of the Ministries of Health or National
Public Health Institutes in 19 countries_Argentina, Australia,
Canada, Chile, China, France, Germany, Hong Kong (special
administrative region), Japan, Madagascar, Mexico, the
Netherlands, New Zealand, Singapore, South Africa, Spain,
Thailand, the United States, and the United Kingdom.
What Did the Researchers Do and Find? As part of
routine surveillance, countries were asked to provide risk
factor data on laboratory-confirmed H1N1 in patients who
were admitted to hospital, admitted to the intensive care
unit (ICU), or had died because of their infection, using a
standardized format. The researchers grouped potential risk
conditions into four categories: age, chronic medical
illnesses, pregnancy (by trimester), and other conditions
that were not previously considered as risk conditions for
severe influenza outcomes, such as obesity. For each risk
factor (except pregnancy), the researchers calculated the
percentage of each group of patients using the total number
of cases reported in each severity category (hospitalization,
admission to ICU, and death). To evaluate the risk associated
with pregnancy, the researchers used the ratio of pregnant
women to all women of childbearing age (age 15–49 years)
at each level of severity to describe the differences between
levels.
The researchers were able to collect data on approximately
70,000 patients requiring hospitalization, 9,700 patients
admitted to the ICU, and 2,500 patients who died from
H1N1 infection. The proportion of patients with H1N1 with
one or more reported chronic conditions increased with
severity—the median was 31.1% of hospitalized patients,
52.3% of patients admitted to the ICU, and 61.8% of patients
who died. For all levels of severity, pregnant women in their
third trimester consistently accounted for the majority of the
total of pregnant women. The proportion of patients with
obesity increased with increasing disease severity—median
of 6% of hospitalized patients, 11.3% of patients admitted to
the ICU, and 12.0% of all deaths from H1N1.
What Do These Findings Mean? These findings show
that risk factors for severe H1N1 infection are similar to those
for seasonal influenza, with some notable differences: a
substantial proportion of people with severe and fatal cases
of H1N1 had pre-existing chronic illness, which indicates that
the presence of chronic illness increases the likelihood of
death. Cardiac disease, chronic respiratory disease, and
diabetes are important risk factors for severe disease that
will be especially relevant for countries with high rates of
these illnesses. Approximately 2/3 of hospitalized people and
40% of people who died from H1N1 infection did not have
any identified pre-existing chronic illness, but this study was
not able to comprehensively assess how many of these cases
had other risk factors, such as pregnancy, obesity, smoking,
and alcohol misuse. Because of large differences between
countries, the role of risk factors such as obesity and
pregnancy need further study—although there is sufficient
evidence to support vaccination and early intervention for
pregnant women. Overall, the findings of this study reinforce
the need to identify and target high-risk groups for
interventions such as immunization, early medical advice,
and use of antiviral medications.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001053.
N WHO provides a Global Alert and Response (GAR) with
updates on a number of influenza-related topics
N The US Centers for Disease Control and Prevention
provides information on risk factors and H1N1
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